Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lapatinib-associated toxicity and practical management recommendations.

Beverly Moy1, Paul E Goss

  • 1Massachusetts General Hospital Cancer Center, Gillette Center for Women's Cancers, Lawrence House, LRH 304, Boston, MA 02114, USA. bmoy@partners.org

The Oncologist
|August 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026
Same author

Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster Randomized Clinical Trial.

JAMA internal medicine·2026
Same author

Guidance for Community Engagement With Underserved Populations in Cancer Care.

JCO oncology practice·2026
Same author

Current landscape of sequencing ADCs in metastatic breast cancer.

Therapeutic advances in medical oncology·2025
Same author

Improving adjuvant endocrine therapy initiation among patients with breast cancer: a nurse-led, culturally sensitive pilot study.

Breast cancer research and treatment·2025
Same author

Development and refinement of a nurse-led, culturally sensitive intervention for adjuvant endocrine therapy initiation among patients with breast cancer.

European journal of oncology nursing : the official journal of European Oncology Nursing Society·2025

Lapatinib effectively treats ErbB-2-overexpressing breast cancer, including metastatic and inflammatory types. This review details lapatinib

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lapatinib is an oral receptor tyrosine kinase inhibitor targeting ErbB-1 and ErbB-2.
  • Clinical trials demonstrate lapatinib's efficacy in ErbB-2-overexpressing breast cancer.

Purpose of the Study:

  • To review lapatinib-associated toxicities.
  • To provide practical management recommendations for lapatinib toxicity.

Main Methods:

  • Review of phase II and III clinical trial data.
  • Analysis of reported adverse events and toxicity profiles.

Main Results:

  • Lapatinib shows activity in metastatic, inflammatory, and potentially brain metastatic breast cancer.
  • Common toxicities include diarrhea and rash; cardiac toxicity is rare.

Related Experiment Videos

Conclusions:

  • Lapatinib is a valuable treatment option for specific breast cancer subtypes.
  • Understanding and managing lapatinib's toxicity profile is crucial for patient care.